Work

A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.2669.2669

Authors: Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Harry Paul Erba, Ronald Sobecks, Anjali Advani, Julie Nichols, Josephine Chan, Matt Kalaycio

Institutions: Cleveland Clinic, University of Michigan

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980249347

FWCI:

Cites:

Cited by:

Related to: 10